Appropriate Injection Intervals of Dupilumab in Patients With Adult Atopic Dermatitis: A Step Toward Developing...

Area of Science:

• Dermatology
• Immunology
• Pharmacology

Background:

• Growing demand for less frequent dupilumab injections in atopic dermatitis (AD) patients.
• Need for real-world data on successful dupilumab dose reduction strategies.
• Treatment burden and side effects drive interest in extended dosing intervals.

Purpose of the Study:

• Assess efficacy of a patient-centered dupilumab tapering regimen.
• Propose guidelines for patient selection, dosing intervals, and tapering timing.
• Evaluate dupilumab dose reduction in moderate-to-severe adult AD.

Main Methods:

• Single-center retrospective study of adult AD patients on dupilumab.
• Inclusion criteria: moderate-to-severe AD, ≥16 weeks of treatment.
• Interval prolongation considered for patients with controlled Eczema Area and Severity Index (EASI) and inflammatory markers after ≥40 weeks.

Main Results:

• 11 of 52 patients successfully extended dupilumab intervals to 3-4 weeks.
• Tapering group had lower BMI; mean treatment duration before tapering was 53.27 weeks.
• Patients achieving EASI < 4 and IgE < 1,000 IU/mL at week 40 maintained low scores post-tapering.

Conclusions:

• Extended dupilumab dosing intervals show sustained effectiveness.
• Dose tapering is a potential option for non-obese AD patients with a significant clinical response.
• Guidelines for tapering include EASI < 4 and IgE < 1,000 IU/mL at 40 weeks.